FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and biotechnology, and may be used for intensifying the vascular growth in ischemic tissues. An agent under the invention contains the plasmid construct pC4W-hVEGFopt bearing the optimised gene hVEGFopt of vascular endothelial growth factor, and in addition the plasmid construct pC4W-hHGFopt bearing the optimized gene hHGFopt hepatocyte growth factor. The method under the invention consists in the intramuscular introduction of a mixture of the plasmid constructs pC4W-hVEGFopt and pC4W-hHGFopt in 0.9% NaCl in ischemic extremity.
EFFECT: use of inventions allows providing effective angiogenesis in ischemic tissue.
4 cl, 1 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GENETIC ENGINEERING STRUCTURE FOR ANGIOGENESIS STIMULATION | 2019 |
|
RU2737487C1 |
| METHOD OF ANGIOGENESIS AUGMENTATION IN ISCHEMIC TISSUES AND COMBINATION DRUG FOR METHOD IMPLEMENTATION | 2015 |
|
RU2628706C2 |
| METHOD FOR GENE THERAPY TREATMENT OF DIABETIC FOOT SYNDROME | 2015 |
|
RU2599507C1 |
| AGENT FOR TREATMENT OF ISCHEMIC LESIONS OF TISSUES AND METHOD OF ITS USE | 2012 |
|
RU2522778C2 |
| OPTIMIZED NUCLEOTIDE SEQUENCE AND PHARMACEUTICAL COMPOSITIONS BASED THEREON WITH SUSTAINED VEGF TRANSGENE EXPRESSION | 2015 |
|
RU2612497C2 |
| METHOD FOR SIMULATING ANGIOGENESIS, TREATING NEUROGENERATIVE DISEASES AND REGENERATING SKELETAL MUSCLE USING PLASMID CONSTRUCTS WITH GENES FOR ANGIOGENIC AND NEUROTROPHIC FACTORS | 2020 |
|
RU2805082C2 |
| METHOD OF ESTIMATING ANGIOGENIC POTENTIAL OF PROGENOTOR CELLS IN PATIENTS WITH CARDIOVASCULAR DISEASES | 2011 |
|
RU2548801C2 |
| METHOD FOR STIMULATING REGENERATIVE PROCESSES IN ISCHEMIC TISSUES | 2011 |
|
RU2497529C2 |
| CODON-OPTIMISED SEQUENCES AND PHARMACEUTICAL COMPOSITION FOR RECOVERY OF BLOOD VESSELS | 2014 |
|
RU2557385C1 |
| METHOD OF COMBINED SURGICAL STIMULATION OF LOWER EXTREMITY CHRONIC LOWER LIMB NEOANGIOGENESIS | 2018 |
|
RU2703395C1 |
